tiprankstipranks
Advertisement
Advertisement
Perspective Therapeutics shareholders approve directors and governance items
PremiumCompany AnnouncementsPerspective Therapeutics shareholders approve directors and governance items
1M ago
Perspective Therapeutics Showcases Strong Interim Radiopharma Data
Premium
Company Announcements
Perspective Therapeutics Showcases Strong Interim Radiopharma Data
1M ago
Options Volatility and Implied Earnings Moves This Week, May 18 – May 22, 2026
Premium
Market News
Options Volatility and Implied Earnings Moves This Week, May 18 – May 22, 2026
2M ago
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances
PremiumCompany AnnouncementsPerspective Therapeutics Highlights Q1 Progress and Strengthened Finances
2M ago
Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update
Premium
Company Announcements
Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update
2M ago
Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data
Premium
Company Announcements
Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data
3M ago
Perspective Therapeutics price target raised to $8 from $7 at UBS
PremiumThe FlyPerspective Therapeutics price target raised to $8 from $7 at UBS
4M ago
Perspective Therapeutics price target raised to $13 from $11 at B. Riley
Premium
The Fly
Perspective Therapeutics price target raised to $13 from $11 at B. Riley
4M ago
Perspective Therapeutics price target raised to $8 from $7 at UBS
Premium
The Fly
Perspective Therapeutics price target raised to $8 from $7 at UBS
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100